Biopsy Devices Market Size, Share, Trends, Growth, and Forecasts for 2025 - 2032

Biopsy Devices Market Size and Forecast Analysis

Market Overview

The global biopsy devices market size is likely to be valued at US$ 6.3 billion in 2025 and is expected to reach US$ 10.4 billion by 2032, growing at a CAGR of 7.4% from 2025 to 2032. A major growth factor for the biopsy devices market is the rising prevalence of cancer, driving demand for early and accurate diagnostic tools.

The biopsy devices market is witnessing strong growth, driven by the rising global incidence of cancer and the increasing need for early and accurate diagnosis. Advancements in minimally invasive technologies-such as image-guided biopsy systems, robotic-assisted tools, and liquid biopsy techniques-are enhancing diagnostic precision and patient comfort. Key industry players like Cardinal Health, Hologic, and Danaher are leading innovation in this space. Additionally, expanding healthcare access in emerging markets, government-supported cancer screening initiatives, and growing awareness of preventive care are accelerating adoption. The market is also benefiting from the trend toward eco-friendly and sustainable medical devices aligned with global healthcare goals.

Market Dynamics

Drivers

Rising Global Cancer Incidence:

The rising global cancer incidence is a major growth driver for the biopsy devices market. Cancer cases are projected to increase by 77%, from 20 million in 2022 to over 35 million by 2050. Older adults, especially those over 65-who accounted for nearly half of cancer diagnoses in 2022-represent a growing patient base. This trend, particularly strong in North America and Europe, is fueling demand for advanced cancer diagnostic tools, including minimally invasive biopsy devices.

For instance, India introduced the MR Fusion Biopsy system in 2024, enhancing prostate cancer diagnosis by integrating MRI and ultrasound. Additionally, companies like Medtronic are advancing AI-powered biopsy systems to boost accuracy and reduce procedural errors. These innovations in image-guided biopsy technology are accelerating adoption across emerging markets, supported by expanding healthcare infrastructure and national cancer screening programs.

Advancements in Minimally Invasive Technologies:

Innovations in biopsy devices-such as vacuum-assisted biopsy (VAB), core needle biopsy (CNB), and fine needle aspiration biopsy (FNAB)-are significantly transforming cancer diagnostics. These minimally invasive biopsy techniques reduce patient discomfort, lower complication rates, and shorten recovery time. Among them, ultrasound-guided biopsies gained notable traction in 2023 due to their cost-effectiveness, real-time imaging capabilities, and lack of radiation exposure, making them widely adopted in hospitals and diagnostic centers.

For instance, the U.S. Veterans Health Administration recognizes ultrasound-guided VAB as an effective outpatient procedure that minimizes tissue damage and recovery time. Similarly, the Centers for Medicare & Medicaid Services (CMS) support ultrasound-guided biopsies for their diagnostic accuracy and patient safety advantages

Restraints

High Costs of Advanced Devices:

The high cost of advanced biopsy devices remains a major restraint in the global biopsy devices market. Technologies such as robotic-assisted biopsy systems and AI-integrated biopsy platforms require significant research and development investments. Leading companies like Medtronic spend over $2 billion annually on innovation, driving up the production cost and, consequently, the market price of these devices. This makes it challenging for healthcare providers in low-resource settings to adopt high-end diagnostic tools.In cost-sensitive markets, particularly across developing nations, limited healthcare funding and minimal insurance coverage hinder the adoption of advanced biopsy technologies. According to the WHO, nearly 50% of the global population lacks access to essential healthcare services, underscoring affordability as a key barrier to market growth.

Opportunities

• Liquid Biopsy Growth: The growth of non-invasive liquid biopsy techniques is creating major opportunities, especially in oncology, for early cancer detection and ongoing monitoring. In the U.S. alone, this market is expected to reach US$ 10.5 billion by 2031, reflecting steady expansion over the coming years.
• Emerging Markets: Developing regions such as Asia-Pacific and Latin America present untapped potential due to improving healthcare infrastructure. India’s adoption of advanced biopsy systems, such as the MR Fusion Biopsy machine in 2024, and China’s share of the East Asia market in 2022 highlight significant growth prospects.
• Personalized Medicine: The shift toward personalized medicine drives demand for precise diagnostic tools. Innovations such as smart biopsy devices with RF spectroscopy, developed by Dune Medical in 2019, improve tissue characterization, creating new market avenues for tailored cancer diagnostics.

Category-wise Analysis

Product Type Insights

• Needle-based biopsy instruments held a dominant position in the biopsy devices market in 2023, accounting for approximately 48.28% of market share. Their widespread use in diagnosing breast, lung, and prostate cancers is driven by their minimally invasive nature, affordability, and compatibility with imaging technologies like ultrasound and MRI. These features make them a preferred choice in hospitals and diagnostic centers, especially for accurate and real-time cancer diagnosis.
• Vacuum-assisted biopsy devices are expected to see strong growth from 2025 to 2032 due to their ability to collect larger, high-quality tissue samples, especially for breast and prostate cancer diagnosis. Their integration with ultrasound and stereotactic imaging improves targeting accuracy and diagnostic reliability. These minimally invasive biopsy techniques are increasingly preferred in hospitals and diagnostic centers for efficient and precise cancer detection.

Application Type Insights

• Breast biopsy held the largest share of the biopsy devices market in 2023, driven by the high global incidence of breast cancer, which recorded over 2.26 million new cases in 2020. It remains the most commonly diagnosed cancer among women worldwide. Advancements in imaging-guided techniques such as 3D mammography, stereotactic imaging, and ultrasound-guided biopsies have significantly improved diagnostic accuracy and early detection. The widespread availability of specialized breast biopsy systems in hospitals and dedicated breast care centers further supports the segment’s dominance, enhancing patient access to minimally invasive, image-guided diagnostic procedures.
• Prostate biopsy is expected to experience rapid growth from 2025 to 2032, driven by the rising incidence of prostate cancer and the adoption of advanced diagnostic methods. In 2020, prostate cancer impacted approximately 1.4 million people worldwide, making it one of the most common cancers in men. Fusion biopsy-combining MRI and ultrasound-is increasingly preferred for its superior accuracy in targeting suspicious lesions. This technology enhances early detection while minimizing unnecessary tissue sampling. The global fusion biopsy market is projected to grow substantially, with estimates indicating it could reach nearly US$ 2.9 billion by 2033, reflecting growing demand for precision-guided cancer diagnostics.

End Use Insights

• Hospitals and breast care centers dominate the biopsy devices market as key end users, widely supported by advanced imaging infrastructure and skilled professionals. Though the 68% share isn't officially confirmed, their leading role is well established. Reimbursement policies, such as the US$ 1,400 Medicare rate for breast biopsies in 2021, further drive adoption and accessibility in this segment.
• Diagnostic and imaging centers are expected to grow rapidly in the biopsy devices market, driven by rising demand for outpatient procedures, lower operational costs, and expanding access to advanced imaging technologies like MRI and ultrasound. Their ability to deliver timely, image-guided biopsies in a cost-effective setting makes them an increasingly preferred option across both urban and semi-urban healthcare systems.

Regional Insights

North America Biopsy Devices Market Trends

• U.S.: The U.S. dominated the biopsy devices market in 2023 with 43.1% global share, driven by high cancer rates, advanced diagnostic technology, and over 3 million annual breast biopsies. Innovations like the Mammotome AutoCore and US$6.8 billion in cancer funding support strong growth. Favorable reimbursement policies boost adoption across hospitals and imaging centers.
• Canada: Canada’s biopsy devices market is growing due to government-funded cancer screening programs, advanced imaging technologies, and improved access to minimally invasive biopsy procedures.
• Mexico: Mexico’s market growth is fueled by rising cancer awareness, public health screening initiatives, and expanding diagnostic infrastructure, especially for breast and prostate cancer detection.

Europe Biopsy Devices Market Trends

• Germany: In 2023, Germany led the European biopsy devices market with a 26% share, supported by advanced diagnostic infrastructure, strong government-funded cancer screening programs, and a high concentration of key biopsy device manufacturers. The country’s focus on early cancer detection and minimally invasive biopsy procedures continues to drive market expansion.
• U.K.: The U.K. followed closely in market share, fueled by NHS-led screening initiatives and the adoption of advanced biopsy technologies such as MRI-guided and ultrasound-guided systems. Strong public healthcare investment and rising cancer awareness contribute to the growing demand for biopsy devices across the country.

Asia-Pacific Biopsy Devices Market Trends

• China: China led the East Asia biopsy devices market in 2022, driven by rising cancer incidence, rapid healthcare infrastructure growth, and strong government backing. Initiatives like the Healthy China 2030 plan and continued investment in advanced diagnostic technologies, including ultrasound and MRI-guided biopsy systems, position China as the dominant force in the Asia-Pacific biopsy devices market.
• Japan: Japan plays a major role in the East Asia biopsy devices market, supported by a growing elderly population, high cancer screening rates, and strong adoption of minimally invasive biopsy technologies. Government initiatives and modern healthcare facilities drive demand for image-guided and core needle biopsy systems, particularly in breast, lung, and gastrointestinal cancer diagnostics.

Competitive Landscape

The biopsy devices market is driven by innovation in AI-integrated, minimally invasive diagnostics. Leaders like Myriad Genetics and BD expand through acquisitions and affordable solutions, while Unilabs’ partnership with GE Healthcare boosts AI integration. Hologic and Danaher focus on sustainability, and global reach is strengthened through strategic R&D, partnerships, and cost-effective technologies targeting emerging and price-sensitive markets.

Key Developments

• 2024: Medtronic launched the Fusion Biopsy System, a robotic-assisted platform for prostate biopsies, enhancing precision with AI integration.
• 2023: Hologic opened an Innovation Centre in France, focusing on advanced biopsy solutions for breast healthcare.
• 2021: Biocept partnered with Quest Diagnostics to offer next-generation sequencing (NGS)-based liquid biopsy testing for lung cancer, expanding non-invasive diagnostic options.

Companies Covered in Biopsy Devices Market

• Cardinal Health, Inc.
• Hologic, Inc.
• Danaher Corporation
• CONMED Corporation
• Cook Medical
• DTR Medical Ltd.
• INRAD, Inc.
• Devicor Medical Products, Inc.
• TransMed7, LLC
• Olympus Corporation
• Others